An evaluation of the effectiveness of HCV genotype 1 treatment with Harvoni® (ledipasvir/sofosbuvir) as measured by a sustained virological response (SVR) of 12 weeks in the MassHealth fee-for-service and Primary Care Clinician plan population. The analysis concluded that treatment was associated with a a high rate of SVR12, which means that Hepatitis C is not detected in the blood after 12 weeks.
Poster
Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1: A Retrospective Cohort Study in a Medicaid Population
Bonnie C. Greenwood, PharmD, BCPS
Director, Clinical Programs, Clinical Pharmacy Services
Pavel Lavitas, PharmD, BCPS
Clinical Team Lead, Clinical Pharmacy Services
Mylissa Price, MPH, RPh
Director - Clinical Account Management, Clinical Pharmacy Services
Karen Clements, ScD
Senior Project Director, Research and Evaluation
Kimberly Lenz, PharmD, MBA, FAMCP
Senior Pharmacy Director, MassHealth/Office of Clinical Affairs
UMASS_Poster_AMCP2017_EffectLedSofandPredTFinMemHepC_CPS_v4_2017.pdf